These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28596091)

  • 41. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
    Zeng Y; Moscicki AB; Sahasrabuddhe VV; Garcia F; Woo H; Hsu CH; Szabo E; Dimond E; Vanzzini S; Mondragon A; Butler V; DeRose H; Chow HS
    BMC Cancer; 2019 Apr; 19(1):290. PubMed ID: 30935375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentary.
    Menon S; Rossi R; Kariisa M; Callens S
    Virol J; 2018 Aug; 15(1):129. PubMed ID: 30115083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.
    Meites E; Kempe A; Markowitz LE
    MMWR Morb Mortal Wkly Rep; 2016 Dec; 65(49):1405-1408. PubMed ID: 27977643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New research progress of the safety of human papillomavirus vaccine].
    Chen W
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):428-434. PubMed ID: 33730840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
    Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
    PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human papillomavirus epidemiology and vaccine recommendations: selected review of the recent literature.
    Seyferth ER; Bratic JS; Bocchini JA
    Curr Opin Pediatr; 2016 Jun; 28(3):400-6. PubMed ID: 27093357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Chesson HW; Curtis CR; Gee J; Bocchini JA; Unger ER;
    MMWR Recomm Rep; 2014 Aug; 63(RR-05):1-30. PubMed ID: 25167164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
    Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?
    Osazuwa-Peters N
    Vaccine; 2013 Nov; 31(47):5500-5. PubMed ID: 24095883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
    J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
    Stokley S; Jeyarajah J; Yankey D; Cano M; Gee J; Roark J; Curtis RC; Markowitz L; ;
    MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):620-4. PubMed ID: 25055185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HPV vaccination in head and neck HPV-related pathologies.
    Wierzbicka M; Józefiak A; Jackowska J; Szydłowski J; Goździcka-Józefiak A
    Otolaryngol Pol; 2014; 68(4):157-73. PubMed ID: 24981297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Arbyn M; Gultekin M; Morice P; Nieminen P; Cruickshank M; Poortmans P; Kelly D; Poljak M; Bergeron C; Ritchie D; Schmidt D; Kyrgiou M; Van den Bruel A; Bruni L; Basu P; Bray F; Weiderpass E
    Int J Cancer; 2021 Jan; 148(2):277-284. PubMed ID: 32638362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.